HomeAI · summaries
Storia in 2 fonti
Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple Sclerosis
Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple Sclerosis
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
morningstar.com
Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple Sclerosis
Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple Sclerosis
- ·
ecodibergamo.it
Teva e Polpharma Biologics annunciano un accordo di licenza globale relativo a un candidato biosimilare per Ocrevus® (ocrelizumab) nella…
Teva Pharmaceuticals International GmbH, una controllata di Teva Pharmaceutical Industries Ltd (NYSE: e TASE: TEVA), e Polpharma Biologics International AG oggi hanno annunciato…